The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate
Authors:
- 13 May 2022
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 238, 114458
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nature Microbiology, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoVChemBioChem, 2020
- Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C ProteaseJournal of Medicinal Chemistry, 2019
- 4-Iminooxazolidin-2-one as a Bioisostere of the Cyanohydrin Moiety: Inhibitors of Enterovirus 71 3C ProteaseJournal of Medicinal Chemistry, 2018
- Structure–activity relationship study of peptidomimetic aldehydes as enterovirus 71 3C protease inhibitorsEuropean Journal of Medicinal Chemistry, 2016
- An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule ChemotherapyJournal of Medicinal Chemistry, 2016
- Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus 71 3C ProteaseJournal of Medicinal Chemistry, 2015
- Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitorsExpert Opinion on Therapeutic Patents, 2009
- Mechanism of the Maturation Process of SARS-CoV 3CL ProteaseJournal of Biological Chemistry, 2005